Current Neurology and Neuroscience Reports

, Volume 9, Issue 5, pp 341–342 | Cite as

Alemtuzumab versus interferon beta-1a in early multiple sclerosis

  • Dennis Bourdette
  • Vijayshree Yadav
Clinical Trials Report


Multiple Sclerosis Chronic Lymphocytic Leukemia Alemtuzumab Natalizumab Immune Thrombocytopenic Purpura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Goodin DS, Cohen BA, O’Connor P, et al.: Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 71:766–773.PubMedCrossRefGoogle Scholar
  2. 2.
    Ali EN, Healy BC, Stazzone LA, et al.: Daclizumab in treatment of multiple sclerosis patients. Mult Scler 2009, 15:272–274.PubMedCrossRefGoogle Scholar
  3. 3.
    Bielekova B, Howard T, Packer AN, et al.: Effect of anti- CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009, 66:483–489.PubMedCrossRefGoogle Scholar
  4. 4.
    Hauser SL, Waubant E, Arnold DL, et al.: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676–688.PubMedCrossRefGoogle Scholar
  5. 5.
    Rose JW, Burns JB, Bjorklund J, et al.: Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007, 69:785–789.PubMedCrossRefGoogle Scholar
  6. 6.
    Fraser G, Smith CA, Imrie K, et al.: Alemtuzumab in chronic lymphocytic leukemia. Curr Oncol 2007, 14:96-109.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Department of NeurologyOregon Health & Science UniversityPortlandUSA
  2. 2.PortlandUSA

Personalised recommendations